Victory Capital Management
KYMR icon

Victory Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Victory Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.52M Buy
74,340
+6,345
+9% +$545K ﹤0.01% 1189
2026
Q1 		$5.66M Buy
67,995
+909
+1% +$72K ﹤0.01% 1280
2025
Q4 		$5.22M Buy
67,086
+35,797
+114% +$2.42M ﹤0.01% 1298
2025
Q3 		$1.77M Buy
31,289
+1,656
+6% +$74.7K ﹤0.01% 1631
2025
Q2 		$1.29M Buy
29,633
+16,593
+127% +$571K ﹤0.01% 1735
2025
Q1 		$357K Sell
13,040
-6,859
-34% -$250K ﹤0.01% 2102
2024
Q4 		$801K Buy
19,899
+12,643
+174% +$571K ﹤0.01% 1891
2024
Q3 		$343K Buy
7,256
+205
+3% +$9.05K ﹤0.01% 2103
2024
Q2 		$210K Sell
7,051
-24
-0.3% -$831 ﹤0.01% 2192
2024
Q1 		$284K Buy
+7,075
New +$253K ﹤0.01% 2134
2022
Q1 		– Sell
-5,607
Closed -$356K – 2772
2021
Q4 		$356K Sell
5,607
-595
-10% -$34.7K ﹤0.01% 2325
2021
Q3 		$364K Buy
6,202
+1,023
+20% +$59.3K ﹤0.01% 2320
2021
Q2 		$251K Buy
+5,179
New +$225K ﹤0.01% 2473

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Victory Capital Management's KYMR Position: Q2 2026 in Review

Victory Capital Management increased its Kymera Therapeutics (KYMR) stake by 9.3% in Q2 2026, buying an estimated $545K and bringing the position to 74,340 shares worth $8.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1189.

Victory Capital Management first reported a position in KYMR in Q2 2021 and has held it in 13 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Victory Capital Management held 74,340 shares of Kymera Therapeutics worth $8.52M as of Q2 2026.
  • Victory Capital Management bought 6,345 Kymera Therapeutics shares in Q2 2026, an estimated $545K.
  • Kymera Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1189 holding.
  • Victory Capital Management first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.